← FDA DRUG APPROVALS

FDA ANDA · ANDA214870

METHYLPREDNISOLONE ACETATE

Sponsor: WILSHIRE PHARMS INC

APPLICATION
ANDA214870
TYPE
ANDA
ORIGINAL APPROVAL
2023-01-03
LATEST ACTION
2024-06-03
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

METHYLPREDNISOLONE ACETATEPrescription
METHYLPREDNISOLONE ACETATE 80MG/ML · INJECTABLE · INJECTION
METHYLPREDNISOLONE ACETATEPrescription
METHYLPREDNISOLONE ACETATE 40MG/ML · INJECTABLE · INJECTION

Approval history

2024-06-03Labeling · Supplement 6 · standardAP
2023-05-10Manufacturing (CMC) · Supplement 1 · unknownAP
2023-01-03UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →